KalVista Pharmaceuticals (KALV) Operating Leases (2019 - 2025)
KalVista Pharmaceuticals recorded quarterly Operating Leases of $4.0 million in Q3 2025, down 7.18% quarter-over-quarter from $4.3 million in Q2 2025, and down 19.43% year-over-year from $5.0 million in Q3 2024.
KalVista Pharmaceuticals' Operating Leases history runs 7 years deep, the most recent figure standing at $4.0 million for Q3 2025.
- In Q3 2025, Operating Leases fell 19.43% year-over-year to $4.0 million; the TTM figure through Jul 2025 stood at $4.0 million (down 19.43% YoY), while the FY2025 annual figure was $4.3 million, down 28.01% from the prior year.
- Operating Leases came in at $4.0 million for Q3 2025 at KalVista Pharmaceuticals, down from $4.3 million in the prior quarter.
- In the past five years, Operating Leases ranged from a high of $8.0 million in Q3 2022 to a low of $1.1 million in Q1 2021.
- A 5-year average of $5.9 million and a median of $6.3 million in 2024 frame the typical range for Operating Leases.
- Across the five-year window, Operating Leases surged 567.81% in 2021 and slumped 33.73% in 2024, its largest moves.
- KalVista Pharmaceuticals' Operating Leases stood at $6.2 million in 2021, then rose by 23.79% to $7.7 million in 2022, then retreated by 15.04% to $6.5 million in 2023, then tumbled by 32.22% to $4.4 million in 2024, then retreated by 9.42% to $4.0 million in 2025.
- According to Business Quant data, Operating Leases over the past three periods registered $4.0 million, $4.3 million, and $4.4 million for Q3 2025, Q2 2025, and Q4 2024 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | KalVista Pharmaceuticals | 1.44 Bn | 1.25 Bn | 56.41 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jul 31, 2025 | 4.02 Mn |
| Apr 30, 2025 | 4.33 Mn |
| Dec 31, 2024 | 4.44 Mn |
| Oct 31, 2024 | 4.34 Mn |
| Jul 31, 2024 | 4.99 Mn |
| Apr 30, 2024 | 6.02 Mn |
| Jan 31, 2024 | 6.26 Mn |
| Oct 31, 2023 | 6.55 Mn |
| Jul 31, 2023 | 6.87 Mn |
| Apr 30, 2023 | 7.15 Mn |
| Jan 31, 2023 | 7.42 Mn |
| Oct 31, 2022 | 7.71 Mn |
| Jul 31, 2022 | 8.01 Mn |
| Apr 30, 2022 | 7.21 Mn |
| Jan 31, 2022 | 7.47 Mn |
| Oct 31, 2021 | 6.22 Mn |
| Jul 31, 2021 | 6.47 Mn |
| Apr 30, 2021 | 5.05 Mn |
| Jan 31, 2021 | 1.12 Mn |
| Oct 31, 2020 | 932,000.00 |
| Jul 31, 2020 | 1.01 Mn |
| Apr 30, 2020 | 1.06 Mn |
| Jan 31, 2020 | 926,000.00 |
| Oct 31, 2019 | 1.05 Mn |
| Jul 31, 2019 | 1.18 Mn |